Anticoagulation in Cirrhosis - IMPORTAL study (Meta-analysis)
- Improved Overall survival (HR 0.6) with anticoagulation (VKA) in Cirrhotics, independent of portal vein recanalization rate
- Portal hypertensive bleeding - same between groups.
- Non-PH bleeding:
- 80% of patients had main PV thrombus, with half patients had complete PVT
- Median duration of VKA Rx = 9 months. Overall median FU - 27 months.
- This was an independent patient level data Meta-analysis of 500 patients, with liver transplantation as competing event. Every study had treatment and no treatment arms.
Exclusions: Tumoral PVT
Limitations: Generally, patients with higher CP scores / bilirubin tended not to receive anticoagulation. This was however adjusted for, in multivariate analysis
Comments
Post a Comment